OL Oncology Letters 1792-1074 1792-1082 D.A. Spandidos 10.3892/ol.2017.5834 OL-0-0-5834 Articles Clinical outcomes and prognostic factors of resected pancreatic neuroendocrine neoplasms: A single-center experience in China JinKaizhou 1 2 3 * LuoGuopei 1 2 3 * XuJin 1 2 3 * ZhangBo 1 2 3 LiuChen 1 2 3 JiShunrong 1 2 3 LiuLiang 1 2 3 LongJiang 1 2 3 NiQuanxing 1 2 3 YuXianjun 1 2 3 Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, P.R. China Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, P.R. China Pancreatic Cancer Institute, Fudan University, Shanghai 200032, P.R. China Correspondence to: Professor Xianjun Yu, Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, 270 Dong An Road, Shanghai 200032, P.R. China, E-mail: yuxianjun@fudanpci.org

Contributed equally

 05 2017 09 03 2017 13 5 3163 3168 14082016 28112016 Copyright © 2017, Spandidos Publications 2017

The aim of the present study was to investigate the clinical, pathological and prognostic characteristics of Chinese patients with resected pancreatic neuroendocrine neoplasms (p-NENs). Data from patients who were surgically treated and pathologically diagnosed with p-NENs at the Department of Pancreatic Oncology of the Fudan University Shanghai Cancer Center (Shanghai, China), between January 2003 and July 2015, were evaluated using univariate and multivariate analyses. A total of 162 patients with p-NENs met the criteria of the present study and were included in the analysis. Patients with poorly differentiated pancreatic neuroendocrine carcinoma (p-NEC) exhibited a significantly increased rate of lymph node metastasis, as compared with patients with grade (G)1/G2 pancreatic neuroendocrine tumors (p-NETs) (62.5 vs. 20.5%, P=0.003). Univariate analysis identified that the following factors led to decreased overall survival (OS): Lymph node metastasis (P=0.001, vs. the absence of lymph node metastasis); distant metastasis (P=0.043, vs. the absence of distant metastasis); resection margin R1/R2 (P=0.030, vs. R0 resection); NEC G3 (P<0.001, vs. NET G1). Following the multivariate analysis, NEC G3 remained a statistically significant risk factor (HR=12.593; 95% CI, 3.476–45.622; P<0.001, vs. NET G1/G2). Furthermore, according to the proliferation marker protein Ki-67 staining index, assigning a grade using the proliferative index (G1, ≤5%; G2, >5–20%; G3, >20%) was more efficient for prognostic stratification compared with the European Neuroendocrine Tumor Society (Berlin, Germany)/World Health Organization (Geneva, Switzerland) 2010 grading classification. The present study indicated that p-NEC was an important predictor of decreased OS in Chinese patients. Furthermore, a Ki-67 staining index of 5% represented a more efficient value for the distinction between G1 and G2.

 pancreas neuroendocrine neoplasm clinical outcome prognostic factor Introduction

Pancreatic neuroendocrine neoplasms (p-NENs) originate from pancreatic neuroendocrine cells, and have increased in incidence in American and Asian patients during the past 20 years (1,2). To improve prognosis, Capella et al (3) developed a clinicopathological classification in 1995 according to clinical, radiographical and histopathological features. Based on this stratification, the World Health Organization (WHO; Geneva, Switzerland) published a classification system in 2000 that distinguishes well-differentiated endocrine tumors from well-differentiated and poorly differentiated endocrine carcinomas (4). Subsequently, in 2010, the WHO updated this classification system to reflect the proliferation marker protein Ki-67 index and mitotic count (5). In this revised classification system, p-NENs are classified as neuroendocrine tumor (NET) grade (G)1 (Ki-67 ≤2%), NET G2 (Ki-67 >2–20%), neuroendocrine carcinoma (NEC) G3 (Ki-67 >20%) and mixed adenoneuroendocrine carcinoma (5).

In 2006 the European Neuroendocrine Tumor Society (ENETS; Berlin, Germany), and in 2010 the American Joint Cancer Committee (Chicago, IL, USA), advocated tumor-node-metastasis (TNM) staging systems for the prognosis of p-NENs (6,7), which referenced previous results from retrospective studies highlighting potential prognostic factors (5,8). Conversely, according to hormone secretion status and clinical presentation, p-NENs are divided into functioning and non-functioning tumors (9). Non-functioning p-NENs may also secrete elevated amounts of hormones while remaining asymptomatic (10). Therefore, non-functioning p-NENs frequently present later in the course of the disease with symptoms resulting from local expansion or distant metastasis (11).

Surgical resection is the only potentially curative therapy for p-NENs, and palliative surgery is also an accepted course of action in cases of liver metastatic disease (12–15). With the development of surgical technology, improved long-term survival of patients with liver-metastatic p-NENs following cytoreductive surgery has also been recently reported (16). However, certain patients exhibit a short survival period following curative surgery and the significance of prognostic factors following surgical resection remains unclear (17). A unified standard to identify critical prognostic factors in p-NENs remains to be performed. Therefore, in the present study the clinical characteristics and prognostic factors of Chinese patients with p-NENs following surgical treatment were analyzed, in order to identify potential risk factors and to detail the outcomes of p-NEN treatment.

 Materials and methods <sec> <title>Patient selection

The present study retrospectively analyzed the medical records of a prospectively maintained database. Between January 2003 and July 2015, 162 patients were pathologically diagnosed with p-NEN and surgically treated at the Department of Pancreatic Oncology of the Fudan University Shanghai Cancer Center (Shanghai, China). The following eligibility criteria were applied (Fig. 1): i) Patients exhibited histologically confirmed p-NENs; ii) patients underwent surgery exclusively at the Fudan University Shanghai Cancer Center; iii) patients did not exhibit p-NET G3, which was defined as NET with high proliferative activity; iv) patients did not present with an unresectable primary tumor or have a history of other types of cancer.

 Tumor characteristics

Patient demographics (age and gender), hormone secretion status (functioning or non-functioning) and tumor characteristics (size, location and presence of lymph node/distant metastasis) are presented in Table I. The WHO 2010 grading classifications and ENETS 2006 TNM staging system were used to assess the clinical outcomes of patients with p-NEN.

 Follow-up and survival

Follow-up was performed via telephone, clinic visit, or outpatient visit between January 2015 and September 2015. Medical records of the included patients were reviewed to collect the following information: Age, gender, hormone secretion status, tumor size, tumor location, tumor invasion, lymphatic metastasis, distant metastasis, surgical approach, surgical margin status, ENETS 2006 TNM staging and WHO 2010 grading. A complete dataset was obtained following the exclusion of patients who succumbed to other factors during follow-up. The data were collected in a prospective manner.

 Statistical analysis

Survival estimates were constructed using the Kaplan-Meier estimator method and survival curves were compared using the log-rank test. Differences between NET G1/G2 and NEC G3 were compared by the χ2 test. Univariate and multivariate Cox proportional hazards models were used to investigate the effects of several prognostic factors. Statistically significant factors following the univariate analysis were included in the multivariate analysis. Statistical analyses were performed using SPSS software (version 22.0; IBM SPSS, Armonk, NY, USA). P<0.05 was considered to indicate a statistically significant difference.

 Results <sec> <title>Patient characteristics

The patient clinicopathological data following diagnosis are summarized in Table I. The mean age (± standard deviation) of the patients was 51.2±12.6 years and 42.6% of the patients were male. A total of 141 patients (87.0%) presented with a non-functioning tumor, whereas 21 patients (13.0%) presented with a functioning tumor. The mean tumor diameter was 4.1±2.8 cm. In 64 (39.5%) patients, the primary disease site was the pancreatic head. A total of 40 (24.7%) patients were pathologically confirmed to exhibit lymph node invasion, whereas 13 (8.0%) patients exhibited distant metastases.

All patients with locoregional or metastatic disease received surgical treatment. Pancreatoduodenectomy, distal pancreatectomy and local resection of the pancreatic tumor were the most frequently performed surgical procedures. R0 resection was performed in 147 (90.7%) patients, whereas the surgery was palliative in 15 (9.3%) cases. There were 40 (24.7%), 77 (47.5%), 32 (19.8%) and 13 (8.0%) cases, classified as stage I, II, III and IV, respectively, according to the 2006 ENETS staging system. All 13 patients with stage IV p-NEN presented with a liver metastasis at the time of diagnosis.

The WHO 2010 grading classification was performed for all patients, yielding a distribution of 79 (48.8%), 67 (41.3%) and 16 (9.9%), G1, G2 and G3 cases, respectively. Details of the surgical procedures and features are presented in Table II. Patients with p-NEC exhibited a significantly increased lymph node metastasis rate, compared with patients with G1/G2 p-NETs (62.5 vs. 20.5%, respectively, P=0.003).

 Survival analyses

The presence of lymphatic metastasis [hazard ratio (HR)=4.802; 95% confidence interval (CI), 1.824–12.645; P=0.001], distant metastasis (HR=3.267; 95% CI, 1.038–10.284; P=0.043), and R1/R2 resection (HR=3.277; 95% CI, 1.119–9.592; P=0.030) led to a decrease in overall survival (OS) compared with their absence (Table III). By contrast, gender, age, surgical approach, primary tumor size, hormone status, vessel invasion and perineural invasion had no significant effect on OS.

According to the WHO 2010 grading system, the differences in the survival time of patients classified as G1 and G3 (HR=28.134; 95% CI, 6.219–127.272; P<0.001) were statistically significant. However, a statistically significant difference between G1 and G2 was not observed (HR=2.605; 95% CI, 0.688–9.866; P=0.159). Furthermore, Ki-67 staining analysis defined a proliferative index of ≤5% as G1, between 5 and 20% as G2, and >20% as G3, providing a more efficient stratification of Chinese patients with p-NENs (G1 vs. G2, HR=4.470; 95% CI, 1.273–15.699; P=0.019; G1 vs. G3, HR=27.857; 95% CI, 7.058–109.944; P<0.001), as compared with the ENETS/WHO classification systems (Fig. 2).

In Table IV, when the Cox proportional hazards model was adjusted for grade, residual tumor classification, lymphatic metastasis and distant metastases, NEC G3 was a significant factor for poor prognosis on multivariate analysis (HR=12.593; 95% CI, 3.476–45.622; P<0.001, vs. NET G1/G2).

 Discussion

Based on the results of the present study, four prognostic factors, including lymphatic metastasis, distant metastasis, R1/R2 resection and p-NEC, predicted a poor prognosis following univariate analysis, and were subsequently used in multivariate analysis. p-NEC was an independent predictor of poor prognosis in patients with p-NEN following multivariate analysis. In addition, p-NEC exhibited increased development of lymph node metastasis compared with G1/G2 p-NET.

Conversely, the present single-center study was not able to distinguish a difference in OS between G1 and G2 tumors, using 2% as the threshold value of the Ki-67 index. The following grading index thresholds classified Chinese patients with p-NENs into three distinct survival groups more efficiently than the WHO 2010 grading classification: G1 ≤5%; G2 >5–20%; and G3 >20%.

The WHO 2010 grade classification system (5) was determined to be an independent predictor of clinical outcomes, thereby corroborating previously published studies (18,19). However, Bettini et al (20) published conflicting results, in which the Ki-67 index was not demonstrated to have predictive value between G1 and G2 tumors. Furthermore, certain studies have demonstrated that a Ki-67 index >5% is the most efficient predictor of recurrence following resection for p-NENs (21,22). In a multicenter study of 202 p-NEN cases, it was revealed that patients with a Ki-67 index of >5% had a notably unfavorable prognosis compared with patients with a Ki-67 index of >2% (8). Rindi et al (23) also demonstrated that a Ki-67 index of 5% is more efficient, compared with 2%, for distinguishing between G1 and G2. In the receiver operating characteristic analysis of that study, the optimal threshold value for the prediction of tumor-associated mortality at five years was identified to be a Ki-67 index of ≥4.85 (23). These findings suggest that a Ki-67 index of 5% is a more efficient threshold value to distinguish between G1 and G2 in patients with p-NENs. Therefore, the revision of the Ki-67 index threshold value for classifying G1/G2 tumors from 2 to 5% is advised.

p-NEC exhibits a poor prognosis (24) and previous evidence has demonstrated the decreased survival rate of patients with p-NEC (25,26). Furthermore, increased lymph node metastasis in p-NEC was observed in the present study. This difference suggested increased malignant biological behavior in p-NEC, which was consistent with other studies (19,27). Therefore, radical surgery with lymphadenectomy is typically recommended for the treatment of localized p-NEC (28).

There were several limitations to the present study. The mean duration of follow-up was 30.3 months, which was shorter compared with other p-NEN studies. The use of an increased sample size is necessary to confirm potential prognostic factors associated with an obvious decrease in survival. Furthermore, relapse-free survival was not analyzed due to the limitation of data integrity, and more effective models are essential in order to reduce loss to follow-up.

In conclusion, the WHO grade classification is a key prognostic factor, while p-NEC is a crucial predictor of poorer OS in Chinese patients with p-NENs. A Ki-67 staining index of 5% is a more efficient threshold value for the identification of G1 and G2. Therefore, the results of the present study suggest that the threshold for classifying G1/G2 tumors be revised from 2 to 5% in patients with p-NENs.

 Acknowledgements

The present study was supported in part by the Sino-German Center (grant no. GZ857), the Science Foundation of Shanghai (grant no. 13ZR1407500) and the National Science Foundation of China (grant no. 81101807).

 References YaoJCHassanMPhanADagohoyCLearyCMaresJEAbdallaEKFlemingJBVautheyJNRashidAEvansDBOne hundred years after ‘carcinoid’: Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United StatesJ Clin Oncol2630633072200810.1200/JCO.2007.15.437718565894 TsaiHJWuCCTsaiCRLinSFChenLTChangJSThe epidemiology of neuroendocrine tumors in Taiwan: A nation-wide cancer registry-based studyPLoS One8e62487201310.1371/journal.pone.006248723614051 CapellaCHeitzPUHöflerHSolciaEKlöppelGRevised classification of neuroendocrine tumours of the lung, pancreas and gutVirchows Arch425547560199510.1007/BF001993427697211 SolciaEKlöppelGSobinLHHistological Typing of Endocrine TumorsWHO International Histological Classification of TumorsSpringerBerlin, Germany2000 RindiGARBosmanFTea: Nomenclature and classification of neuroendocrine neoplasms of the digestive systemBosmanTCarneiroFHrubanRIn: Bosman T, Carneiro F, Hruban R, et al (eds)WHO Classification of Tumours of the Digestive System4thLyon, FranceInternational Agency for Research on Cancer (IARC)34172010 RindiGKlöppelGAlhmanHCaplinMCouvelardAde HerderWWEriksssonBFalchettiAFalconiMKomminothPTNM staging of foregut (neuro)endocrine tumors: A consensus proposal including a grading systemVirchows Arch449395401200610.1007/s00428-006-0250-116967267 EdgeSBBDRComptonCCeaAJCC Cancer Staging ManualNew York, NYSpringer2010 PanzutoFBoninsegnaLFazioNCampanaDBrizziPia MCapursoGScarpaADe BraudFDogliottiLTomassettiPMetastatic and locally advanced pancreatic endocrine carcinomas: Analysis of factors associated with disease progressionJ Clin Oncol2923722377201110.1200/JCO.2010.33.068821555696 KulkeMHBendellJKvolsLPicusJPommierRYaoJEvolving diagnostic and treatment strategies for pancreatic neuroendocrine tumorsJ Hematol Oncol429201110.1186/1756-8722-4-2921672194 DixonEPasiekaJLFunctioning and nonfunctioning neuroendocrine tumors of the pancreasCurr Opin Oncol193035200710.1097/CCO.0b013e328011a23617133109 CheemaAWeberJStrosbergJRIncidental detection of pancreatic neuroendocrine tumors: An analysis of incidence and outcomesAnn Surg Oncol1929322936201210.1245/s10434-012-2285-722350605 HaugvikSPJansonETösterlundPLangerSWFalkRSLaboriKJVestermarkLWGrønbækHGladhaugIPSorbyeHSurgical treatment as a principle for patients with high-grade pancreatic neuroendocrine carcinoma: A nordic multicenter comparative studyAnn Surg Oncol2317211728201610.1245/s10434-015-5013-226678407 KimMJChoiDWChoiSHHeoJSParkHJChoiKKJangKTSungJYSurgical strategies for non-functioning pancreatic neuroendocrine tumoursBr J Surg9915621568201210.1002/bjs.889223027073 HillJSMcPheeJTMcDadeTPZhouZSullivanMEWhalenGFTsengJFPancreatic neuroendocrine tumors: The impact of surgical resection on survivalCancer115741751200910.1002/cncr.2406519130464 FrankoJFengWYipLGenoveseEMoserAJNon-functional neuroendocrine carcinoma of the pancreas: Incidence, tumor biology, and outcomes in 2,158 patientsJ Gastrointest Surg14541548201010.1007/s11605-009-1115-019997980 CusatiDZhangLHarmsenWSHuAFarnellMBNagorneyDMDonohueJHQueFGReid-LombardoKMKendrickMLMetastatic nonfunctioning pancreatic neuroendocrine carcinoma to liver: Surgical treatment and outcomesJ Am Coll Surg215117125201210.1016/j.jamcollsurg.2012.05.00222726741 EkebladSSkogseidBDunderKObergKErikssonBPrognostic factors and survival in 324 patients with pancreatic endocrine tumor treated at a single institutionClin Cancer Res1477987803200810.1158/1078-0432.CCR-08-073419047107 BallianNLoefflerAGRajamanickamVNorstedtPAWeberSMChoCSA simplified prognostic system for resected pancreatic neuroendocrine neoplasmsHPB (Oxford)11422428200910.1111/j.1477-2574.2009.00082.x19768147 FischerLBergmannFSchimmackSHinzUPrießSMüller-StichBPWernerJHackertTBüchlerMWOutcome of surgery for pancreatic neuroendocrine neoplasmsBr J Surg10114051412201410.1002/bjs.960325132004 BettiniRBoninsegnaLMantovaniWCapelliPBassiCPederzoliPFaveGF DellePanzutoFScarpaAFalconiMPrognostic factors at diagnosis and value of WHO classification in a mono-institutional series of 180 non-functioning pancreatic endocrine tumoursAnn Oncol19903908200810.1093/annonc/mdm55218209014 BoninsegnaLPanzutoFPartelliSCapelliPFaveG DelleBettiniRPederzoliPScarpaAFalconiMMalignant pancreatic neuroendocrine tumour: Lymph node ratio and Ki67 are predictors of recurrence after curative resectionsEur J Cancer4816081615201210.1016/j.ejca.2011.10.03022129889 KhanMSLuongTVWatkinsJToumpanakisCCaplinMEMeyerTA comparison of Ki-67 and mitotic count as prognostic markers for metastatic pancreatic and midgut neuroendocrine neoplasmsBr J Cancer10818381845201310.1038/bjc.2013.15623579216 RindiGFalconiMKlersyCAlbarelloLBoninsegnaLBuchlerMWCapellaCCaplinMCouvelardADoglioniCTNM staging of neoplasms of the endocrine pancreas: Results from a large international cohort studyJ Natl Cancer Inst104764777201210.1093/jnci/djs20822525418 Vélayoudom-CéphiseFLDuvillardPFoucanLHadouxJChougnetCNLeboulleuxSMalkaDGuigayJGoereDDebaereTAre G3 ENETS neuroendocrine neoplasms heterogeneousEndocr Relat Cancer20649657201310.1530/ERC-13-002723845449 HashimYMTrinkausKMLinehanDCStrasbergSSFieldsRCCaoDHawkinsWGRegional lymphadenectomy is indicated in the surgical treatment of pancreatic neuroendocrine tumors (PNETs)Ann Surg259197203201410.1097/SLA.000000000000034824253141 StrosbergJRCheemaAWeberJHanGCoppolaDKvolsLKPrognostic validity of a novel american joint committee on cancer staging classification for pancreatic neuroendocrine tumorsJ Clin Oncol2930443049201110.1200/jco.2011.29.4_suppl.17721709192 WongJFulpWJStrosbergJRKvolsLKCentenoBAHodulPJPredictors of lymph node metastases and impact on survival in resected pancreatic neuroendocrine tumors: A single-center experienceAm J Surg208775780201410.1016/j.amjsurg.2014.04.00324997491 Garcia-CarboneroRSorbyeHBaudinERaymondEWiedenmannBNiederleBSedlackovaEToumpanakisCAnlaufMCwiklaJBENETS consensus guidelines for high-grade gastroenteropancreatic neuroendocrine tumors and neuroendocrine carcinomasNeuroendocrinology103186194201610.1159/00044317226731334

Flow chart of the process of patient selection. G, grade; p-NET, pancreatic neuroendocrine tumor.

Kaplan-Meier estimator curves of cumulative survival rates. (A) Stratified by the World Health Organization 2010 grading system. (B) Stratified by proliferation marker protein Ki-67 index.

Clinical, surgical and pathological characteristics of the study population (n=162).

Characteristic Total, n (%)
Mean age ± SD, years 51.2±12.6
Gender
  Male 69 (42.6)
  Female 93 (57.4)
Hormone secretion status
  Functioning 21 (13.0)
  Non-functioning 141 (87.0)
Mean tumor size ± SD, cm 4.1±2.8
Location
  Head 64 (39.5)
  Body and tail 95 (58.6)
  Multicentricity 3 (1.9)
Lymph node metastasis 40 (24.7)
Distant metastasis 13 (8.0)
Surgical approach
  PD/PPPD 42 (26.0)
  DP 88 (54.3)
  LP 24 (14.8)
  TP 8 (4.9)
R0 resection 147 (90.7)
ENETS stage
  I 40 (24.7)
  II 77 (47.5)
  III 32 (19.8)
  IV 13 (8.0)
2010 WHO grading classification
  NET G1 79 (48.8)
  NET G2 67 (41.3)
  NEC G3 16 (9.9)

SD, standard deviation; PD, pancreatoduodenectomy; PPPD, pylorus-preserving PD; DP, distal pancreatectomy; LP, local resection of pancreatic tumor; TP, total pancreatectomy; ENETS, European Neuroendocrine Tumor Society; WHO, World Health Organization; NET, neuroendocrine tumor; G, grade; NEC, neuroendocrine carcinoma.

Surgical procedures and features of the patients with pancreatic neuroendocrine neoplasms (n=162).

Characteristic NET G1/G2 (n=146) NEC G3 (n=16)
Tumor size, mean ± SD, cm 4.05±2.75 4.84±3.21
Location, n (%)
  Head 59 (40.4) 5 (31.2)
  Body and tail 84 (57.5) 11 (68.8)
  Multicentricity 3 (2.1) 0 (0.0)
Lymph node metastasis, n (%) 30 (20.5) 10 (62.5)
Distant metastasis, n (%) 10 (6.9) 3 (18.8)
Surgical approach, n (%)
  PD/PPPD 38 (36.0) 4 (25.0)
  DP 78 (53.4) 10 (62.5)
  LP 24 (13.7) 0 (0.0)
  TP 6 (4.1) 2 (12.5)
R0 resection, n (%) 132 (90.4) 15 (93.8)
ENETS stage, n (%)
  I 39 (26.7) 1 (6.3)
  II 72 (49.3) 5 (31.2)
  III 25 (17.1) 7 (43.8)
  IV 10 (6.9) 3 (18.8)

NET, neuroendocrine tumor; NEC, neuroendocrine carcinoma; G, grade; SD, standard deviation; PD, pancreatoduodenectomy; PPPD, pylorus-preserving PD; DP, distal pancreatectomy; LP, local resection of pancreatic tumor; TP, total pancreatectomy; ENETS, European Neuroendocrine Tumor Society.

Univariate analysis of the clinical factors influencing the prognosis of patients with pancreatic neuroendocrine neoplasms.

Univariate analysis
Variable prognostic factor Mean survival time, months Hazard ratio 95% CI P-value
Gender
  Male 84 – – –
  Female 126 0.476 0.174–1.174 0.147
Age, years
  ≤51 109 – – –
  >51 91 0.996 0.384–2.384 0.994
Surgical approaches
  PD/PPPD 87 – – –
  DP 116 0.789 0.263–2.263 0.672
  LP 96 0.611 0.118–3.118 0.558
  TP 44 1.723 0.196–15.196 0.624
Primary tumor size, cm
  ≤4 118 – – –
  >4 88 1.516 0.570–4.570 0.404
Hormone status
  Functioning   56 – – –
  Non-functioning 111 1.792 0.231–13.231 0.576
Lymph node metastasis
  No 120 – – –
  Yes 71 4.802 1.824–12.824 0.001a
Vessel invasion
  No 113 – – –
  Yes 81 2.380 0.911–6.911 0.077
Perineural invasion
  No 113 – – –
  Yes 84 1.445 0.531–3.531 0.471
Distant metastasis
  No 115 – – –
  Yes 56 3.267 1.038–10.038 0.043a
Resection
  R0 115 – – –
  R1/R2 62 3.277 1.119–9.119 0.030a
Ki-67 (ENETS/WHO 2010)
  ≤2 126 – – –
  >2–20 88 2.605 0.688–9.688 0.159
  >20 21 28.134 6.219–127.219 <0.001a
Ki-67 modified
  ≤5 128 – – –
  >5–20 80 4.470 1.273–15.273 0.019a
  >20 21 27.857 7.058–109.058 <0.001a

Statistically significant. CI, confidence interval; PD, pancreatoduodenectomy; PPPD, pylorus-preserving PD; DP, distal pancreatectomy; LP, local resection of pancreatic tumor; LN lymph node; proliferation marker protein Ki-67; ENETS, European Neuroendocrine Tumor Society; WHO, World Health Organization.

Multivariate analysis of the clinical factors influencing the prognosis of patients with pancreatic neuroendocrine neoplasms.

Multivariate analysis
Variable prognostic factor Hazard ratio 95% CI P-value
Lymph invasion
  No – – –
  Yes 2.904 0.970–8.970 0.057
Distant metastasis
  No – – –
  Yes 2.460 0.391–15.391 0.338
Resection
  R0 – – –
  R1/R2 3.695 0.696–19.696 0.125
Tumor grade
  NET G1/G2 – – –
  NEC G3 12.593 3.476–45.476 <0.001a

Statistically significant.